We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Inspiration Healthcare Group Plc | IHC | London | Ordinary Share |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
12.85 | 12.85 | 12.85 | 12.85 | 12.85 |
Industry Sector |
---|
HEALTH CARE EQUIPMENT & SERVICES |
Announcement Date | Type | Currency | Dividend Amount | Ex Date | Record Date | Payment Date |
---|---|---|---|---|---|---|
03/10/2023 | Interim | GBP | 0.00205 | 23/11/2023 | 24/11/2023 | 22/12/2023 |
03/05/2023 | Final | GBP | 0.0041 | 29/06/2023 | 30/06/2023 | 28/07/2023 |
04/10/2022 | Interim | GBP | 0.00205 | 24/11/2022 | 25/11/2022 | 28/12/2022 |
04/05/2022 | Final | GBP | 0.0041 | 30/06/2022 | 01/07/2022 | 29/07/2022 |
05/10/2021 | Interim | GBP | 0.00205 | 25/11/2021 | 26/11/2021 | 29/12/2021 |
27/04/2021 | Final | GBP | 0.004 | 01/07/2021 | 02/07/2021 | 30/07/2021 |
06/10/2020 | Interim | GBP | 0.002 | 26/11/2020 | 27/11/2020 | 29/12/2020 |
Top Posts |
---|
Posted at 14/11/2024 17:30 by lammylover Just 2804 shares were traded today and IHC business is worth 4.55% less than it was yesterday.The nonsense that is AIM market and low liquidity / big spreads! |
Posted at 17/6/2024 09:46 by dogwalker No they aren't.If anything, it's the other way round : 'funds' (as you call them) transferring out of the under -performer APH into IHC. Suggest you do the same BH. |
Posted at 28/5/2024 16:08 by mtioc To be fair to Roy Davis, his first "announcement" is suitably decisive. It will be interesting to see his first actions as interim CEO. I hope he gives it a go.Also interesting re Mennen and Redworth. They do not seem like passive public market investors. I am sure they would like the option to acquire IHC cheaply. Much will depend on BGF and Berenberg. If they have had enough, I suspect we will all be put out of our misery at c. 30p. |
Posted at 20/5/2024 08:39 by techno20 And another purchase. Interesting portfolio of businesses, heavily healthcare related. IHC would fit well. |
Posted at 20/5/2024 06:20 by lindowcross I note Mennen Medical recently upped its stake in IHC to around 5%. I wonder why?It is part of Redworth Capital Group Redworth Capital is a multinational investment house with offices in Philadelphia (USA), Tel Aviv (ISR) and London (UK), engaged in diversified business segments: Medical Devices and Technologies, Real Estate and Entertainment |
Posted at 02/5/2024 08:42 by lammylover From what I can see on twitter, its business as usual at IHC:1/5/24 2 day training session in London, Home Care Team getting info on latest advances in healthcare tech. 30/4/24 Advertising for Senior Business Development Manager position. 29/4/24 Attending conference in B/ham Hopefully the delayed contract is just a blip, and progress will be made this year.. |
Posted at 01/2/2024 15:32 by trmum Thanks MTIOC, having stalked this board for a while now I can only offer the observation that when I found out there were nice new Porsches in the car park at IHC, I assumed the good times were about to role.That now seems a bit tone deaf by Campbell et al. And my assumptions also terrible. Old chair seemed happy with everything, as you say, hope new chair evaluates decision making over past few years, not excuses ("error-prone"), and takes some decisive action. |
Posted at 31/1/2024 18:27 by hedgehog 100 Dogwalker,We didn't know today that a covenant waiver would be necessary, so it's a bit of a stretch to call it good news. I think that's why IHC is down 29.91% today (down 16p, from 53.5p to 37.5p). |
Posted at 04/1/2024 17:50 by mtioc Geovest, I agree. Really hard to sell in US without local knowledge and presence. Each state can have different regulations and distributors. Like you I wonder if it is too small.This suggests that management have a reasonable confidence in FDA approval for ventilators. If approval received and IHC manages to achieve actual sales (both big ifs), it would shift valuation. |
Posted at 04/9/2023 09:55 by mtioc Just catching up. I have owned this for a while.This is a poor, early and big miss of a self-selected target. I have not seen Liberum note, but crudely appears to be a £3m revenue miss at a GM of 48%, so c. £1.5m profit hit, but seems to be £1.2m in broker's estimate. IHC has just appointed new brokers and PR advisers to generate institutional interest that could include supporting acquisitions. The one thing they could not afford to do was “miss their numbers”. I think there are some fundamental problems. Before the SLE acquisition, the group was a distributor of others’ products into the UK and Eire market. The acquisition added the complexity of manufacturing and worldwide distribution. It seems this has been too much for the management team: lack of controls led to a working capital cash suck (that is slowly unwinding under an interim and now a new CFO); they overspent (£1-2m?) on the new facility that has numerous vanity features, and their reporting/forecastin There needs to be change. The chair has been involved since 2001 and since the float in 2015. A new, possibly exec chair, with Danagher/GE sector/ops experience should come in. That chair should have a wide remit to review the strategy and team competency. Four non-execs is probably at least one too many for a company this size and, given the finance issues, the finance related NED should also step down. That should allow the appointment to be cost neutral. I wonder how active the institutions led by BGF will be - it is very small. I still think there is value in IHC’s position in neonatal distribution and equipment. On the equipment side, SLE’s automated oxygen control algorithms and equipment appear quite unique. The upside is US approval for its system. Even if that does not happen, the business should be cash generative and I suspect trade or PE would pay more than the year end EV (where I expect the working capital to swing the other way to turn net debt into a cash position). I will hold for a while longer. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions